You can buy or sell Zealand Pharma and other stocks, options, ETFs, and crypto commission-free!
Zealand Pharma A/S American Depositary Shares, also called Zealand Pharma, is a biotechnology company that engages in the discovery, design and development of peptide based medicines. Its products include Soliqua and Lyxumia. Read More The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on October 19, 1998 and is headquartered in Glostrup, Denmark.
52 Week High
52 Week Low
Seeking AlphaMay 14
Zealand Pharma's dasiglucagon successful in late-stage study; shares up 4% premarket
Zealand Pharma (NASDAQ:ZEAL) is up 4% premarket on light volume in reaction to its announcement of positive results from a confirmatory Phase 3 clinical trial evaluating dasiglucagon for the treatment of severe hypoglycemia (low blood sugar) in diabetes.
Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome
Press release - No. 10 / 2019 Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome The Phase 3 extension trial will evaluate long-term safety and efficacy of glepaglutide and enrolls short bowel syndrome (SBS) patients that have completed the pivotal Phase 3 trial. The pivotal Phase 3 registration trial with glepaglutide for the treatment of SBS remains on track with results expected in 2020. Glepaglutide is a long-acting GLP-2 an...
Available May 16